Is ANAEMIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ANAEMIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 84 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ANAEMIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ANAEMIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ANAEMIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ANAEMIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ANAEMIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ANAEMIA: 84
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ANAEMIA is a reported side effect: 2.5233%

FDA reports of any drug causing ANAEMIA : 66542
Average percentage for all medicated patients where ANAEMIA is reported as a complication: 0.4170%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ANAEMIA:

ASPIRIN (7819 patients)
FOSAMAX (7678 patients)
HEPARIN SODIUM INJECTION (5267 patients)
ZOMETA (4897 patients)
VIOXX (4857 patients)
LASIX (4629 patients)
ACCUTANE (4471 patients)
PREDNISONE (3831 patients)
RIBAVIRIN (3775 patients)
COUMADIN (3076 patients)
REVLIMID (3065 patients)
AREDIA (2992 patients)
OMEPRAZOLE (2915 patients)
FUROSEMIDE (2905 patients)
LISINOPRIL (2814 patients)
DEXAMETHASONE (2750 patients)
LIPITOR (2743 patients)
FOLIC ACID (2710 patients)
PEGASYS (2688 patients)
NEXIUM (2653 patients)
PLAVIX (2530 patients)
PREDNISOLONE (2410 patients)
ALLOPURINOL (2380 patients)
ACETAMINOPHEN (2296 patients)
ARANESP (2235 patients)
PROTONIX (2197 patients)
METHOTREXATE (2130 patients)
DIGOXIN (2055 patients)
PRILOSEC (2040 patients)
SYNTHROID (2017 patients)
NORVASC (1938 patients)
HUMIRA (1935 patients)
AMBIEN (1888 patients)
NEURONTIN (1877 patients)
POTASSIUM CHLORIDE (1873 patients)
SIMVASTATIN (1872 patients)
DECADRON (1870 patients)
CARBOPLATIN (1862 patients)
WARFARIN SODIUM (1859 patients)
ATENOLOL (1842 patients)
REBETOL (1759 patients)
REMICADE (1688 patients)
LEVAQUIN (1687 patients)
HYDROCHLOROTHIAZIDE (1672 patients)
PEG-INTRON (1671 patients)
CELEBREX (1655 patients)
ZOLOFT (1655 patients)
ZOFRAN (1632 patients)
OXYCONTIN (1619 patients)
CISPLATIN (1597 patients)
LEVOTHYROXINE SODIUM (1596 patients)
ZOCOR (1571 patients)
CYCLOPHOSPHAMIDE (1499 patients)
XANAX (1494 patients)
TOPROL-XL (1481 patients)
VICODIN (1472 patients)
PREDNISONE TAB (1468 patients)
GLEEVEC (1466 patients)
ALBUTEROL (1460 patients)
PREVACID (1446 patients)
ATIVAN (1444 patients)
SEROQUEL (1439 patients)
COPEGUS (1409 patients)
PERCOCET (1406 patients)
VITAMIN D (1396 patients)
LORAZEPAM (1394 patients)
AMLODIPINE (1313 patients)
IBUPROFEN (1289 patients)
DIOVAN (1283 patients)
METFORMIN HCL (1263 patients)
MORPHINE (1223 patients)
FERROUS SULFATE TAB (1218 patients)
LEXAPRO (1208 patients)
INSULIN (1207 patients)
PROCRIT (1201 patients)
MULTI-VITAMINS (1200 patients)
LOVENOX (1199 patients)
VELCADE (1192 patients)
METOPROLOL TARTRATE (1179 patients)
OXYCODONE HCL (1157 patients)
PAXIL (1147 patients)
THALIDOMIDE (1137 patients)
FORTEO (1126 patients)
FLUOROURACIL (1124 patients)
GABAPENTIN (1089 patients)
LANTUS (1087 patients)
COMPAZINE (1050 patients)
DOXORUBICIN HCL (1043 patients)
VITAMIN B-12 (1030 patients)
AMOXICILLIN (1026 patients)
TAXOTERE (1021 patients)
EPOGEN (1020 patients)
CALCIUM (1004 patients)
COREG (999 patients)
IRON (995 patients)
LYRICA (974 patients)
PANTOPRAZOLE (969 patients)
BACTRIM (966 patients)
NITROGLYCERIN (961 patients)
FAMOTIDINE (955 patients)
LORTAB (952 patients)
DURAGESIC-100 (951 patients)
AVANDIA (943 patients)
CHEMOTHERAPEUTICS NOS (938 patients)
FLUCONAZOLE (938 patients)
LANSOPRAZOLE (928 patients)
PROZAC (927 patients)
COLACE (921 patients)
ZANTAC (920 patients)
AVONEX (920 patients)
ALDACTONE (920 patients)
FENTANYL (914 patients)
TAXOL (911 patients)
SPIRONOLACTONE (906 patients)
ALENDRONATE SODIUM (902 patients)
NEUPOGEN (901 patients)
REGLAN (893 patients)
VANCOMYCIN (882 patients)
CIPROFLOXACIN (866 patients)
TRAMADOL HCL (865 patients)
VINCRISTINE (860 patients)
ENALAPRIL MALEATE (853 patients)
CYCLOSPORINE (850 patients)
CYMBALTA (849 patients)
CALCIUM CARBONATE (841 patients)
PREMARIN (834 patients)
ACYCLOVIR (826 patients)
ENBREL (817 patients)
GEMZAR (815 patients)
METOPROLOL (802 patients)
RITUXIMAB (801 patients)
CLINDAMYCIN (799 patients)
CARVEDILOL (798 patients)
HEPARIN (796 patients)
PACLITAXEL (794 patients)
GLUCOPHAGE (792 patients)
AVASTIN (788 patients)
SOLIRIS (785 patients)
EXJADE (783 patients)
COZAAR (783 patients)
MORPHINE SULFATE (780 patients)
DIFLUCAN (778 patients)
ZYPREXA (772 patients)
LOPRESSOR (769 patients)
ADVAIR DISKUS 100/50 (769 patients)
RAMIPRIL (762 patients)
ALPRAZOLAM (760 patients)
ACTONEL (756 patients)
ZITHROMAX (753 patients)
BENADRYL (750 patients)
RANITIDINE (749 patients)
CELEXA (746 patients)
DILAUDID (745 patients)
ASCORBIC ACID (736 patients)
AUGMENTIN '125' (730 patients)
ACTOS (730 patients)
EFFEXOR (727 patients)
PEPCID (726 patients)
TAMOXIFEN CITRATE (724 patients)
DOXYCYCLINE (721 patients)
TRACLEER (721 patients)
MYCOPHENOLATE MOFETIL (720 patients)
FLEXERIL (720 patients)
XELODA (717 patients)
PEGINTERFERON ALFA-2A (711 patients)
CRESTOR (710 patients)
GEMCITABINE (709 patients)
RADIATION THERAPY (693 patients)
CLONAZEPAM (690 patients)
FEMARA (686 patients)
INCIVEK (678 patients)
TYLENOL (667 patients)
HERCEPTIN (666 patients)
GLIPIZIDE (662 patients)
BEVACIZUMAB (660 patients)
CYTOXAN (659 patients)
CIPRO (648 patients)
VOLTAREN (645 patients)
MULTI-VITAMIN (643 patients)
METOCLOPRAMIDE (642 patients)
CEPHALEXIN (637 patients)
SPIRIVA (635 patients)
KALETRA (634 patients)
TYLENOL (CAPLET) (631 patients)
ALLEGRA (630 patients)
ONDANSETRON (624 patients)
VITAMIN E (623 patients)
ZYRTEC (622 patients)
TYSABRI (622 patients)
ADRIAMYCIN PFS (622 patients)
NAPROXEN (621 patients)
NEXAVAR (621 patients)
FLOMAX (619 patients)
MAGNESIUM OXIDE (618 patients)
HEPARIN SODIUM (618 patients)
AFINITOR (617 patients)
NEULASTA (616 patients)
FLAGYL (615 patients)
GLYBURIDE (615 patients)
NYSTATIN (614 patients)
PROCRIT /00909301/ (608 patients)
MEGACE (605 patients)
PROMETHAZINE (601 patients)
MIRALAX (600 patients)
METHYLPREDNISOLONE (598 patients)
PROGRAF (586 patients)
MS CONTIN (581 patients)
HYDROCODONE (577 patients)
CLONIDINE (577 patients)
WELLBUTRIN (576 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ANAEMIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.